Abstract

BackgroundHepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths. The average survival and 5-year survival rates of HCC patients still remains poor. Thus, there is an urgent need to better understand the mechanisms of cancer progression in HCC and to identify useful biomarkers to predict prognosis.MethodsPublic data portals including Oncomine, The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) profiles were used to retrieve the HCC-related microarrays and to identify potential genes contributed to cancer progression. Bioinformatics analyses including pathway enrichment, protein/gene interaction and text mining were used to explain the potential roles of the identified genes in HCC. Quantitative real-time polymerase chain reaction analysis and Western blotting were used to measure the expression of the targets. The data were analysed by SPSS 20.0 software.ResultsWe identified 80 genes that were significantly dysregulated in HCC according to four independent microarrays covering 386 cases of HCC and 327 normal liver tissues. Twenty genes were consistently and stably dysregulated in the four microarrays by at least 2-fold and detection of gene expression by RT-qPCR and western blotting showed consistent expression profiles in 11 HCC tissues compared with corresponding paracancerous tissues. Eleven of these 20 genes were associated with disease-free survival (DFS) or overall survival (OS) in a cohort of 157 HCC patients, and eight genes were associated with tumour pathologic PT, tumour stage or vital status. Potential roles of those 20 genes in regulation of HCC progression were predicted, primarily in association with metastasis. INTS8 was specifically correlated with most clinical characteristics including DFS, OS, stage, metastasis, invasiveness, diagnosis, and age.ConclusionThe significantly dysregulated genes identified in this study were associated with cancer progression and prognosis in HCC, and might be potential therapeutic targets for HCC treatment or potential biomarkers for diagnosis and prognosis.Electronic supplementary materialThe online version of this article (doi:10.1186/s13046-016-0403-2) contains supplementary material, which is available to authorized users.

Highlights

  • IntroductionThe average survival and 5-year survival rates of Hepatocellular carcinoma (HCC) patients still remains poor

  • Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths

  • In the present study, using data of mRNA expression, DNA methylation, and clinical data retrieved from Oncomine, Gene Expression Omnibus (GEO), and the The Cancer Genome Atlas (TCGA) cohort, we identified a group of genes associated with cancer progression and prognosis in HCC

Read more

Summary

Introduction

The average survival and 5-year survival rates of HCC patients still remains poor. There is an urgent need to better understand the mechanisms of cancer progression in HCC and to identify useful biomarkers to predict prognosis. The average survival of HCC patients is normally between 6 and 20 months [3], and long-term prognosis is poor with reported 5-year survival rates ranging from 17 to 53 % [4]. There is an urgent need to better understand the mechanism of cancer progression and development in HCC and to identify useful biomarkers for diagnosis and prognosis. In the present study, using data of mRNA expression, DNA methylation, and clinical data retrieved from Oncomine, GEO, and the TCGA cohort, we identified a group of genes associated with cancer progression and prognosis in HCC

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call